http://www.americanbankingnews.com/getthestreet reissued their buy rating on shares of Regeneron Pharms (NASDAQ: REGN) in a report released on Wednesday.
“Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of B . The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”
,” TheStreet’s analyst wrote.
Shares of Regeneron Pharms opened at 167.00 on Wednesday. Regeneron Pharms has a one year low of $102.82 and a one year high of $188.95. The stock’s 50-day moving average is currently $169.5. The company has a market cap of $16.141 billion and a P/E ratio of 24.72.
A number of other analysts have also recently weighed in on REGN. Analysts at Zacks reiterated a neutral rating on shares of Regeneron Pharms in a research note to investors on Monday, February 18th. They now have a $173.00 price target on the stock. Separately, analysts at Deutsche Bank reiterated a buy rating on shares of Regeneron Pharms in a research note to investors on Monday, February 11th. They now have a $190.00 price target on the stock. Finally, analysts at Robert W. Baird reiterated an outperform rating on shares of Regeneron Pharms in a research note to investors on Friday, January 25th. They now have a $205.00 price target on the stock.
Eight equities research analysts have rated the stock with a buy rating, one has assigned an overweight rating, and nine have assigned a hold rating to the company’s stock. The stock presently has an average rating of overweight and a consensus price target of $184.54.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
